LAUSR

Purpose of ReviewTreatment decisions regarding adjuvant endocrine therapy in breast cancer has become increasingly complex, with non-adherence to treatment one of the most crucial issues. We aimed to review the literature on both aspects focusing on new finding regarding assessment, determinants, and interventions of decision-making and adherence to adjuvant endocrine therapy.Recent FindingsA shared decision-making process is wanted by the patients and can improve patient-related outcomes. Information needs, preferences, and values regarding adjuvant endocrine therapy vary widely. Nearly two-thirds of patients do not take the adjuvant endocrine therapy exactly as prescribed either by not initiating, missing doses, or stopping the treatment early.SummaryImplementation of tools for a shared decision can be useful in clinical practice, but further development is needed in the field of adjuvant endocrine therapy. Targeted interventions are desirable to improve patients’ adherence to adjuvant endocrine therapy, thereby improving the quality of care and outcomes in breast cancer.